Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects

Exclusion Criteria

• •Any known severe allergies to yeast products
• •Currently active skin diseases such as psoriasis, atopic dermatitis, allergic contact dermatitis or irritant contact dermatitis
• •Inability to understand informed consent
• •Any medical condition that the investigator feels would interfere with study
• •Any abnormalities on physical exam or screening laboratory studies (to progress to Part II)
• •Agree to discontinue use of prohibited medications at least 4 weeks prior to screening:
• •topical corticosteroids, oral or injectable systemic steroids, systemic immunomodulators (cyclosporine, methotrexate, etc.), oral or topical antihistamines
• •Positive reaction to tuberculin test (PPD) or negative control
• •Negative reaction to initial skin testing for Candida, Trichophyton, or Sodium Laurel Sulfate